Drugs / CS12192
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05922709 | Jul 2023 → Feb 2024 | — | Chipscreen Biosciences, Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-03-24 | Chipscreen Biosciences, Ltd. | Regulatory Chipscreen Biosciences's Original New Drug CS12192: Investigational New Drug (IND) Application Accepted chipscreen.com ↗
On March 23th, 2020, Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) announced that the company’s application for Investigational New Drug (IND) of CS12192 has been accepted by Center for Drug Evaluation, National Medical Products Administration of China (Application No.: CXHL2000118, CXHL2000119). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-03-24 | Chipscreen Biosciences, Ltd. | Chipscreen Biosciences's Original New Drug CS12192: Investigational New Drug (IND) Application Accepted chipscreen.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CS12192 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05922709 ↗ |
| Route | Oral | “Participants receive CS12192 orally single or multiple doses” NCT05922709 ↗ |